Literature DB >> 7296476

The influence of ICRF-159 and levamisole on the incidence of metastases following local irradiation of a solid tumor.

D Baker, W Constable, D Elkon, L Rinehart.   

Abstract

Courses of irradiation consisting of 6000 rad in ten equal fractions over 12 days delivered to KHT sarcomas in mice controlled 55% of the local tumors but 83% of the mice died from metastases. Three strategies to reduce the risk of metastatic spread were tested. The fractionation scheme was changed to deliver the same total dose using a large initial fraction followed by seven equal portions with the same overall time. ICRF-159 was used with the intention of partially synchronizing the tumor growth fraction in a radiosensitive state of the growth cycle and of promoting normalization of the tumor vasculature. Levamisole was used to stimulate the immune system. The combination of ICRF-159 with the eight-fraction radiation course proved to be effective for both increasing local control and decreasing the incidence of metastases. The addition of levamisole did not improve the results obtained with a combination of ICRF-159 and irradiation.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7296476     DOI: 10.1002/1097-0142(19811115)48:10<2179::aid-cncr2820481011>3.0.co;2-u

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

Review 1.  Radiation enhancement of metastasis: a review.

Authors:  C F von Essen
Journal:  Clin Exp Metastasis       Date:  1991 Mar-Apr       Impact factor: 5.150

2.  Combined vindesine and razoxane shows antimetastatic activity in advanced soft tissue sarcomas.

Authors:  Walter Rhomberg; Helmut Eiter; Franz Schmid; Christoph H Saely
Journal:  Clin Exp Metastasis       Date:  2007-10-12       Impact factor: 5.150

3.  A randomized trial comparing cisplatin plus 5-fluorouracil with or without levamisole in operable gastric cancer.

Authors:  J S Choi; K H Lee; M J Ahn; J S Lee; J H Lee; D Y Zang; C W Suh; S W Kim; W G Kim; J C Kim; S K Kim; K C Park; M S Lee; S H Kim
Journal:  Korean J Intern Med       Date:  1997-06       Impact factor: 2.884

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.